5
ALL1
CASI Pharmaceuticals3
Delcath Systems1
Johnson & Johnson Innovative MedicineYear
5
ALL1
20242
20222
2020DEALS // DEV.
5
ALL2
Deals3
DevelopmentsCountry
5
ALL5
U.S.A5
ALL1
Guokang Pharmaceuticals3
Not Applicable1
Roth Capital PartnersTherapeutic Area
5
ALL5
OncologyStudy Phase
5
ALL3
Approved2
Phase IIIDeal Type
2
ALL1
Agreement1
Public OfferingProduct Type
5
ALL1
Large molecule4
Small moleculeDosage Form
3
ALL1
Infusion1
Intravenous Injection1
Subcutaneous InjectionLead Product
5
ALL1
Daratumumab4
MelphalanTarget
3
ALL1
CD382
DNAAelyrin Announces 32-Week Data from Phase 2b of Izokibep in Hidradenitis Suppurativa
Details : Hepzato kit (melphalan) is a combination drug/device product which administers melphalan directly to the liver through the HDS. It is approved for the treatment of metastatic uveal melanoma (mUM).
Brand Name : Hepzato Kit
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 16, 2024
Delcath Announces Poster Presentation at the 2022 ASCO Annual Meeting
Details : Alkeran (melphalan), is designed to administer high-dose chemotherapy to the liver while minimizing systemic exposure and associated side effects via filtration of the chemotherapeutic agent from the blood.
Brand Name : Alkeran
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 09, 2022
Casi Pharmaceuticals Announces Renewal Of Exclusive Distribution Agreement For Evomela® In China
Details : Under the terms of the agreement, China Resources Pharmaceutical Commercial Group International Trading Co., will continue to be the sole distributor for the sale of EVOMELA® (melphalan) for Injection in China.
Brand Name : Evomela
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 04, 2022
Lead Product(s) : Daratumumab,Bortezomib,Melphalan
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : DARZALEX® SC reduces administration time from hours to minutes and demonstrates consistent efficacy with a reduction in administration-related reactions compared to intravenous DARZALEX® (daratumumab).
Brand Name : Darzalex SC
Molecule Type : Large molecule
Upfront Cash : Not Applicable
August 04, 2020
Lead Product(s) : Daratumumab,Bortezomib,Melphalan
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Delcath Systems Prices $22M Public Offering
Details : Delcath intends to use the net proceeds of the offering for working capital and general corporate purposes including the continued development of Melphalan/HDS.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 01, 2020
LOOKING FOR A SUPPLIER?